Role of Alpha-lipoic Acid in Diabetes Melitus Type 1

NCT05679037 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2023-01-10

No results posted yet for this study

Summary

This study aims at investigating the possible effect of alpha-lipoic acid on endothelial dysfunction and atherosclerosis in children with type 1 diabetes mellitus.

Conditions

  • Diabetes MellitusType 1

Interventions

OTHER

Placebo

Inactive capsules

DRUG

Alpha Lipoic Acid 600 MG Oral Capsule

Universal antioxidant

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-31
Primary Completion
2024-10-31
Completion
2024-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05679037 on ClinicalTrials.gov